Addition of PD-1/PD-L1 inhibitors to chemotherapy for triple-negative breast cancer: a meta-analysis

Addition of PD-1/PD-L1 inhibitors to chemotherapy for triple-negative breast cancer: a meta-analysis

BackgroundIn recent years, the addition of immune checkpoint inhibitors (ICI) to chemotherapy (CT) has become a research hotspot in the therapy of metastatic triple-negative breast cancer. Nevertheless, controversial results have been revealed among the published randomized controlled trials. Hence,...

Full description

Bibliographic Details
Main Authors:	Juan Yang, Chen Liu, Yaru Guo, Wenwen Guo, Xiaojin Wu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-02-01
Series:	Frontiers in Oncology
Subjects:	triple-negative breast cancer PD-1/PD-L1 immune checkpoint inhibitors chemotherapy systematic review meta-analysis
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1309677/full

Similar Items

Immunotherapy using PD‑1/PDL-1 inhibitors in triple‑negative breast cancer: a systematic review
by: Dione Tavares, et al.
Published: (2021-12-01)

Mechanisms and Strategies to Overcome PD-1/PD-L1 Blockade Resistance in Triple-Negative Breast Cancer
by: Xingyu Chen, et al.
Published: (2022-12-01)

Research Advances of PD-1/PD-L1 Inhibitors Combined with Angiogenesis Inhibitors in Treatment of Advanced Triple-negative Breast Cancer
by: HUANG Shifen, et al.
Published: (2021-01-01)

Expression of PD-L1 in triple negative breast cancer
by: Gina James Keorges
Published: (2023-03-01)

Efficacy and Safety of PD-1/PD-L1 Inhibitors in Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis
by: Zhen-Yu Li, et al.
Published: (2023-09-01)

Global research trends on anti-PD-1/anti-PD-L1 immunotherapy for triple-negative breast cancer: A scientometric analysis
by: Jinyao Wu, et al.
Published: (2023-01-01)

Efficacy and safety of PD-1 and PD-L1 inhibitors combined with chemotherapy in randomized clinical trials among triple-negative breast cancer
by: Yihang Qi, et al.
Published: (2022-09-01)

Adverse Events of PD-1 or PD-L1 Inhibitors in Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis
by: Yixi Zhang, et al.
Published: (2022-11-01)

Rationale and Clinical Research Progress on PD-1/PD-L1-Based Immunotherapy for Metastatic Triple-Negative Breast Cancer
by: Yifan Ren, et al.
Published: (2022-08-01)

Immunotherapy Targeting PD-1/PD-L1 in Early-Stage Triple-Negative Breast Cancer
by: Tinglin Yang, et al.
Published: (2023-03-01)

PD-1/PD-L1 immune checkpoint inhibitors in metastatic triple-negative breast cancer: a systematic review and meta-analysis
by: Yinan Yu, et al.
Published: (2023-06-01)

Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy
by: Gizem Oner, et al.
Published: (2021-09-01)

Spatial Profile of Tumor Microenvironment in PD-L1-Negative and PD-L1-Positive Triple-Negative Breast Cancer
by: Liubov A. Tashireva, et al.
Published: (2023-01-01)

Immune checkpoint inhibitors plus neoadjuvant chemotherapy in early triple-negative breast cancer: a systematic review and meta-analysis
by: Yuanfang Xin, et al.
Published: (2021-11-01)

Applicability of PD-L1 tests to tailor triple-negative breast cancer treatment in Brazil
by: Kátia Ramos Moreira Leite, et al.
Published: (2021-04-01)

Predictive value of PD-L1 expression to the efficacy of immune checkpoint inhibitors in advanced triple-negative breast cancer: A systematic review and meta-analysis
by: Yingjie Qi, et al.
Published: (2022-12-01)

Disulfiram Improves the Anti-PD-1 Therapy Efficacy by Regulating PD-L1 Expression via Epigenetically Reactivation of IRF7 in Triple Negative Breast Cancer
by: Xin Zheng, et al.
Published: (2021-11-01)

CDK Inhibition Primes for Anti-PD-L1 Treatment in Triple-Negative Breast Cancer Models
by: Anthony Cheung, et al.
Published: (2022-07-01)

Prognostic value of CD8 + PD-1+ immune infiltrates and PDCD1 gene expression in triple negative breast cancer
by: Joe Yeong, et al.
Published: (2019-02-01)

The interaction between the soluble programmed death ligand-1 (sPD-L1) and PD-1+ regulator B cells mediates immunosuppression in triple-negative breast cancer
by: Xuejiao Li, et al.
Published: (2022-07-01)

PD-1/PD-L1 axis in organ fibrosis
by: Youliang Zhao, et al.
Published: (2023-05-01)

PD-1/L1 inhibitor plus chemotherapy in the treatment of sarcomas
by: Zhichao Tian, et al.
Published: (2022-08-01)

PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations
by: Yongshuai Jiang, et al.
Published: (2019-05-01)

Neoadjuvant immunotherapy and chemotherapy regimens for the treatment of high-risk, early-stage triple-negative breast cancer: a systematic review and network meta-analysis
by: Javier Cortes, et al.
Published: (2023-08-01)

Triple Combination Therapy With PD-1/PD-L1, BRAF, and MEK Inhibitor for Stage III–IV Melanoma: A Systematic Review and Meta-Analysis
by: Ye Liu, et al.
Published: (2021-06-01)

Overview of the Cardiotoxicity Induced by PD-1/PD-L1 Immune Checkpoint Inhibitor in Critical Care
by: Ruiting Li, et al.
Published: (2021-06-01)

PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential
by: Tianrui Yang, et al.
Published: (2021-02-01)

Characterization of PD-1/PD-L1 Immune Checkpoint Expression in Osteosarcoma
by: Kazuhiko Hashimoto, et al.
Published: (2020-07-01)

PD-L1 Expression in Mastocytosis
by: Margaret Williams, et al.
Published: (2019-05-01)

Research progress of oncolytic virus combined with PD-1/PD-L1 inhibitors
by: GAN Zi-ying, TANG Hui
Published: (2022-04-01)

Research Progress on Cardiotoxicity of PD-1/PD-L1 Immune Checkpoint Inhibitors
by: YU Lin, et al.
Published: (2021-08-01)

Improving Anti-PD-1/PD-L1 Therapy for Localized Bladder Cancer
by: Florus C. de Jong, et al.
Published: (2021-03-01)

Effectiveness of chemotherapy after anti‐PD‐1 blockade failure for relapsed and refractory Hodgkin lymphoma
by: Beatrice Casadei, et al.
Published: (2020-11-01)

Immunotherapy in combination with chemotherapy in triple-negative breast cancer - the first “target” therapy for the “target” patients’ population
by: Katerina S Grechukhina, et al.
Published: (2019-09-01)

PD-L1 blockade TAM-dependently potentiates mild photothermal therapy against triple-negative breast cancer
by: Chao Wang, et al.
Published: (2023-12-01)

Dostarlimab an Inhibitor of PD-1/PD-L1: A New Paradigm for the Treatment of Cancer
by: Faisal K. Alkholifi, et al.
Published: (2022-11-01)

Immune Checkpoint Inhibitors: Ctla-4 and Pd-1/Pd-l1 in Immunotherapy
by: Kübra KAHVECİ, et al.
Published: (2019-12-01)

Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models
by: Roberto R. Rosato, et al.
Published: (2018-09-01)

Clinical benefit of neoadjuvant anti‐PD‐1/PD‐L1 utilization among different tumors
by: Zhiyang Li, et al.
Published: (2021-03-01)

PD-L1 Protein Expression in Middle Eastern Breast Cancer Predicts Favorable Outcome in Triple-Negative Breast Cancer
by: Sandeep Kumar Parvathareddy, et al.
Published: (2021-01-01)